hotspot -WSS

hotspot

author：explore 2025-09-29 19:06:34 - browse：79

President Biden talking at desk — President Biden on Friday rolled out a new set of initiatives to reduce health care costs, including a crackdown on scam insurance plans. Kevin Dietsch/Getty Images

WASHINGTON (AP) — President Biden on Friday rolled out a new set of initiatives to reduce health care costs: a crackdown on scam insurance plans, new guidance to prevent surprise medical bills and an effort to reduce medical debt tied to credit cards.

Biden’s remarks will build on previous initiatives to limit health care costs, with the Department of Health and Human Services releasing new estimates showing 18.7 million older adults and other Medicare beneficiaries will save an estimated $400 per year in prescription drug costs in 2025 because of the president placing a cap on out-of-pocket spending as part of last year’s Inflation Reduction Act.

Gearing up for his 2024 reelection campaign as inflation remains a dominant concern for voters, the Democratic president has emphasized his policies to help families manage their expenses, as well as a spate of government incentives to encourage private sector development of electric vehicles, clean energy and advanced computer chips.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： How medical schools plan to diversify without affirmative action

WSS

FDA panel endorses Alnylam’s heart drug — after picking it apart

Long Covid needs a new name — and a new frame

Obesity drugs seen as possible treatment for liver disease MASH

Dario to buy mental health app maker Twill in cash and stock deal

Pig kidney works a record two months in donated body

Alabama hospital puts IVF treatments on hold

focus

hotspot

explore

Tori Bowie and the unacceptable rates of Black maternal death

Generate Biomedicines machine learning biotech raises $273M

In age of alternative facts, a scholarly course on calling out crap

Popular nasal decongestant doesn't actually relieve congestion

Duchenne breakthrough therapy leaves behind pioneering families

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Hepatitis C has a cure — but many Americans still lack access to it

Alabama frozen embryo ruling has major implications for IVF clinics

Alkermes shareholders re

New documents shed light on MD Anderson Cancer Institute feud

focus

Walmart eyes Medicare Advantage provider ChenMed

IRA could hurt research into orphan drugs for rare diseases

In utero gene editing: an explainer

FDA panel endorses Alnylam’s heart drug — after picking it apart

Acelyrin, a rare IPO success, stumbles in its first big test

New weight loss drugs vying to be the next Wegovy or Mounjaro

focus

hotspot

knowledge

explore